Compared to the IV infusion of the blockbuster cancer drug Keytruda, subcutaneous Keytruda can cut the time spent in ...

MSD has entered an exclusive licence agreement with Hengrui Pharma for the oral small molecule Lp(a) inhibitor, HRS-5346.

MSD has fleshed out its cardiovascular disease pipeline by licensing an oral Lp (a) inhibitor from China's Jiangsu Hengrui ...

MSD has opened a $1bn facility in Durham located in the US state of North Carolina, to increase vaccine manufacturing capacity.

The Philippine College of Occupational Medicine (PCOM) and healthcare company MSD in the Philippines have joined forces to ...